Artwork

Sisällön tarjoaa Talking About Tumors. Talking About Tumors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

03_05 NSCLC metastatic without driver mutations

31:52
 
Jaa
 

Manage episode 366702187 series 3335024
Sisällön tarjoaa Talking About Tumors. Talking About Tumors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

1. Evidence to support platinum doublets
2. The tale of pemetrexed
3. Immune checkpoint inhibitors alone and in combination
4. Second Line, approach in progression

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Paz-Ares L et al. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0

2. Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231

3. Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009

4. Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774

5. Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865

6. Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/

7. Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232

8. Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3

9. Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102

10. Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375

11. Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470

12. Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196

13. Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

48 jaksoa

Artwork
iconJaa
 
Manage episode 366702187 series 3335024
Sisällön tarjoaa Talking About Tumors. Talking About Tumors tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

1. Evidence to support platinum doublets
2. The tale of pemetrexed
3. Immune checkpoint inhibitors alone and in combination
4. Second Line, approach in progression

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

1. Paz-Ares L et al. Lancet Oncol. 2021;22(2):198-211. doi:10.1016/S1470-2045(20)30641-0

2. Hellmann MD et al. NEJM. 2019;381(21):2020-2031. doi:10.1056/NEJMOA1910231

3. Socinski MA et al. J Thorac Oncol. 2021;16(11):1909-1924. doi:10.1016/J.JTHO.2021.07.009

4. Reck M et al. NEJM. 2016;375(19):1823-1833. doi:10.1056/NEJMOA1606774

5. Paz-Ares L et al. NEJM. 2018;379(21):2040-2051. doi:10.1056/NEJMOA1810865

6. Gandhi L et al. NEJM. 2018;378(22):2078-2092. doi:10.1056/NEJMOA1801005/

7. Scagliotti G et al. Oncologist. 2009;14(3):253-263. doi:10.1634/THEONCOLOGIST.2008-0232

8. Paz-Ares L et al. Lancet Oncol. 2012;13(3):247-255. doi:10.1016/S1470-2045(12)70063-3

9. Paz-Ares LG et al. JCO. 2013;31(23):2895-2902. doi:10.1200/JCO.2012.47.1102

10. Scagliotti GV et al. JCO. 2008;26(21):3543-3551. doi:10.1200/JCO.2007.15.0375

11. Delbaldo C et al. JAMA. 2004;292(4):470-484. doi:10.1001/JAMA.292.4.470

12. Ardizzoni A et al. J Natl Cancer Inst. 2007;99(11):847-857. doi:10.1093/JNCI/DJK196

13. Temel JS et al. NEJM. 2010;363(8):733-742. doi:10.1056/NEJMOA1000678

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

  continue reading

48 jaksoa

Kaikki jaksot

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas